

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Donna MENDRICK et al.)	
Application No.: 09/917,800)	Group Art Unit: 1631
Filed: July 31, 2001)	Examiner: Cheyne Dune Ly
For: Molecular toxicology modeling	<i>)</i>	

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MAIL DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RECEIVED

FEB 2 0 2004.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action or a Notice of Allowance. The Commissioner is hereby authorized to charge \$180.00 as specified by § 1.17(p) to Deposit Account No. 50-0310, for this Information Disclosure Statement under the provisions of 37 C.F.R. § 1.97(c).

Copies of the documents listed are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Attorney Docket No. 44921-5038-US Application No.: 09/917,800

Page 2

This submission does not represent that a search has been made or that no better art exists

and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies a document as "prior art" against any claim in the

application and Applicants determine that the cited document does not constitute "prior art"

under United States law, Applicants reserve the right to present to the office the relevant facts

and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability

of the disclosed invention over the listed documents, should one or more of the documents be

applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby

authorized by this paper to charge any additional fees during the entire pendency of this

application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR**

EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Dated: February 18, 2004

Morgan, Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel: 202-739-5870

Fax: 202-739-3001

Respectfully submitted

Morgan, Lewis & Bockius LLP

Registration No. 43,210

1-WA/2092445.1

INFORMATION DISCLOSURE CITATION			Attorney Docket 44921-5038-US			Application No. 09/917,800	
(Use several sheets if necessary)				Applicant: Donna MENDRICK et al.			
PTO Form 1449			Filing Date: July 31, 2001			Group Art Unit: 1631	
		U.S. PATE	NT DOC	UMENTS			
HilaP E	Patent No. Issue Date		Name		Class	Sub-class	Filing Date
FEB 1 8 200	<u>3</u>			.		REC	EIVED
RADEMAR						FEB 2	0 2004
RADE					-		
	-						
		FOREIGN PA	TENT D	OCUMEN'	rs		<u></u>
	Document	Date C	ountry	Class	Sub Class		anslation
	No.	2002 10 16	D.C.M.	CION		Yes	No
	WO 03/085083	2003-10-16	PCT	C12N C12N			
	WO 03/095624 WO 03/100030	2003-11-20 2003-12-04	PCT PCT	C12N			
	WO 03/100030	2003-12-04	101	CIZIV	<u>.</u>	_	
,		ОТНЕ	R DOCUN	1ENTS		· I	!
	Irizarry et al. (2 31(4):e15, 8 pp	2003), "Summaries of	Affymetrix	GeneChip p	orobe level d	ata," Nucl Ac	ids Res
		2002), "Tumor classif natics 18(1):39-50.	ication by p	partial least s	quares using	microarray g	gene expressio
		· · · · · · · · · · · · · · · · · · ·					
		•					
xaminer:			Dat	e Considered:			
xaminer: -I	nitial if reference consid	lered, whether or not cit	ation is in co	onformance wi	ith MPEP 609	; draw line thr	ough citation if
		ed. Include copy of this					Page 1 of